Antibody-modified chimeric antigen receptor modified T cell and uses thereof
US12358994B2 · kind B2 · utility
0Cited by
1References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 28, 2018 |
| Grant date | Jul 15, 2025 |
| Priority date | — |
| Expiry date | Nov 14, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a T cell expressing an antibody or comprising the coding sequence of the antibody or an expression vector thereof; the antibody contains an optional signal peptide, an antigen binding sequence and a mutant type Fc segment, wherein the mutant type Fc segment is a Fc segment in which amino acid residues at the 17th site and the 79th site of the IgG4 Fc segment shown by SEQ ID NO: 25 are mutated into E and Q respectively. Preferably, the T cell is a CAR-T cell. The present invention further relates to a treatment application of the T cell in malignant tumors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.